Abstract: A hydrophobic drug delivery system that includes a plant derived sterol (stanol) or a sterol (stanol) derived ester, an emulsifier and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system.

Abstract: A method of preparing and composition of bioavailable hydrophobic, poorly water soluble drugs. It uses for example, lecithin, sterol, a calcium salt, and solvent; mixing to form liposomes and then the solvent driven off; the ratios used and physical form differ from others, and maximize performance.

Abstract: Oral dosage compositions for drugs normally given intravenously such as Paclitaxel, containing a plant sterol to enhance solubility and a small intestine efflux inhibitor to prevent P-glycoprotein from being a barrier to absorption.

Abstract: A method of preparing and composition of bioavailable hydrophobic, poorly water soluble drugs. It uses for example, lecithin, sterol, a calcium salt, and solvent; mixing to form liposomes and then the solvent driven off; the ratios used and physical form differ from others, and maximize performance.

Abstract: Oral dosage compositions for drugs normally given intravenously such as Paclitaxel, containing a plant sterol to enhance solubility and a small intestine efflux inhibitor to prevent P-glycoprotein from being a barrier to absorption.

Abstract: A method and composition of preparing bioavailable hydrophobic, poorly water soluble drugs. It uses for example, lecithin, sterol, and solvent; mixing and then the solvent driven off; the ratios used differ from others, and maximize performance.

Abstract: This invention encompasses methods for manufacturing purified, high molecular weight sulfated polysaccharide compositions that inhibit pancreatic cholesterol esterase and lower cholesterol in the blood stream.

Abstract: A hydrophobic drug delivery system that includes a plant derived sterol (stanol) or a sterol (stanol) derived ester, an emulsifier and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system.

Abstract: A hydrophobic drug delivery system that includes a plant derived sterol (stanol), lecithin or a sterol (stanol) derived ester, and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system.

Abstract: The present invention describes a composition that contains a plant sterol or plant stanol or their fatty acid esters and an emulsifier for treating conditions that are related to elevated dihydrotestosterone. The compositions can be prepared in a dry form for use as a food ingredient, tablet or capsule. Alternatively, the compositions can be dissolved in oil.

Abstract: Use of polycosanols to lower egg cholesterol.

Abstract: A hydrophobic drug delivery system that includes a plant derived sterol (stanol), lecithin or a sterol (stanol) derived ester, and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system.

Abstract: A method and composition for inhibiting human cholesterol absorption comprising ingesting a therapeutic amount of an inhibitor of human cholesterol esterase comprising very high molecular weight sulfated polysaccharide having a sulfate to monomer ratio of from 1.0 to 3.0, containing less than about 5.0 wt. percent of sulfated polysaccharides having a molecular weight less than 75,000 Daltons, and containing less than 0.5 weight percent of inorganic sulfate.

Abstract: The invention provides methods for the purification to homogeneity of pancreatic cholesterol esterase in useful quantities from a variety of mammalian species. The gene for a mammalian pancreatic cholesterol esterase has been cloned and sequenced, and is useful for expressing cholesterol esterase in a transformed eukaryotic or prokaryotic cell culture. Thus, methods according to the invention enable the production of large quantities of pancreatic cholesterol esterase for the screening of inhibitors, the production of antibodies, and for commercial purposes related to the alteration of cholesterol/cholesterol ester composition of materials containing free or esterified cholesterol.

Abstract: The invention provides methods for the purification to homogeneity of pancreatic cholesterol esterase in useful quantities from a variety of mammalian species. The gene for a mammalian pancreatic cholesterol esterase has been cloned and sequenced, and is useful for expressing cholesterol esterase in a transformed eukaryotic or prokaryotic cell culture. Thus, methods according to the invention enable the production of large quantities of pancreatic cholesterol esterase for the screening of inhibitors, the production of antibodies, and for commercial purposes related to the alteration of cholesterol/cholesterol ester composition of materials containing free or esterified cholesterol.

Abstract: This invention encompasses methods for inhibiting and/or treating gastric and duodenal ulcers by the administration of purified, high molecular weight sulfated polysaccharide compositions.

Abstract: The invention provides methods for the purification to homogeneity of pancreatic cholesterol esterase in useful quantities from a variety of mammalian species. The gene for a mammalian pancreatic cholesterol esterase has been cloned and sequenced, and is useful for expressing cholesterol esterase in a transformed eukaryotic or prokaryotic cell culture. Thus, methods according to the invention enable the production of large quantities of pancreatic cholesterol esterase for the screening of inhibitors, the production of antibodies, and for commercial purposes related to the alteration of cholesterol/cholesterol ester composition of materials containing free or esterified cholesterol.

Abstract: This invention encompasses a method and compositions which inhibit pancreatic cholesterol esterase and triglyceride lipase and hence, lower cholesterol and triglycerides in the blood stream.

Abstract: This invention encompasses methods for manufacturing purified, high molecular weight sulfated polysaccharide compositions that inhibit pancreatic cholesterol esterase and lower cholesterol in the blood stream.

Abstract: Intestinal cell endogenous heparin mediated absorption of cholesterol or fatty acids in mammals is inhibited through the oral administration of heparin, an active heparin subfraction or heparinase. Suppression of cholesterol esterase-mediated absorption in humans can be inhibited by soluble heparin by two mechanisms, i.e. displacement of the enzyme from the intestinal cell membrane and inhibition of enzymatic activity of the displaced enzyme. A method for recovering a solution of purified human pancreatic cholesterol esterase having a molecular weight of about 100,000 daltons is disclosed. The 100,000 dalton fraction of human pancreatic cholesterol esterase is purified first, by preparing a solution of dialyzed human pancreatic cytosol containing the esterase and other proteins. Next, the solution is passed over a hydroxyapetite column and then eluted to yield all of the molecular weight fractions of the esterase and other proteins in the solution present as a single peak to give a first eluent.